

# Incident AUD diagnosis in patients with obesity and no prior history of AUD

during 12-month follow-up time period  
(comparison between propensity-score matched cohorts)

Population	Semaglutide cohort	Non-GLP-1RAs anti-obesity medications cohort	HR (95% CI)
Overall (n = 26,784/cohort)	0.28% (74)	0.48% (128)	0.56 (0.42–0.75)
Women (n = 17,938/cohort)	0.24% (43)	0.35% (63)	0.66 (0.45–0.98)
Men (n = 7,260/cohort)	0.29% (21)	0.65% (47)	0.43 (0.27–0.72)
age ≤ 55 years (n = 15,791/cohort)	0.32% (51)	0.52% (82)	0.61 (0.43–0.86)
age > 55 years (n = 10,639/cohort)	0.16% (17)	0.33% (35)	0.46 (0.26–0.82)
Black (n = 4,221/cohort)	0.50% (21)	0.45% (19)	1.06 (0.57–1.98)
White (n = 17,956/cohort)	0.21% (37)	0.49% (88)	0.41 (0.28–0.60)
No T2D (n = 17,754/cohort)	0.23% (40)	0.36% (63)	0.63 (0.42–0.93)
T2D (n = 8,817/cohort)	0.41% (36)	0.66% (58)	0.58 (0.38–0.88)

